In this episode of Life Science Success, we sit down with Marc, an entrepreneur, certified coach, and a beacon of leadership in the life sciences and business coaching sectors. Marc shares his journey from the entrepreneurial services group at EY to founding and leading companies in the life sciences field, and how he leverages his vast experience to mentor and inspire others towards professional excellence and personal growth. Tune in for a deep dive into the intersection of business acumen and scientific innovation, and discover Marc's unique approach to fostering success in the competitive world of life sciences. Marc Cote's background includes a transition from being a CPA at Ernst & Young to becoming an entrepreneur and certified coach, focusing on leadership within the life sciences. He credits his father, a second-generation business owner, for influencing his career path and emphasizing the importance of a strong business foundation. During his career, Cote identified a gap in leadership and soft skills training among highly technically trained professionals in the life sciences. He aims to help these individuals realize their potential not only as scientists but also as visionary leaders and effective managers. Cote discusses his journey from consulting at Ernst & Young to launching his own companies that supported biotech and small pharmaceutical companies. He emphasizes the value of leadership coaching to enhance emotional intelligence (EQ), crucial for effective leadership. The podcast conversation covers Cote's approach to coaching, focusing on understanding and leveraging one's strengths and appreciating different leadership styles. He highlights the importance of continuous personal development and adaptability in achieving career advancement within the life sciences.

In this episode of Life Science Success, my guest is Darwin Shurig, founder and CEO of Shurig Solutions. Darwin brings strategic value to medical device, life science, and pharma companies. Darwin is responsible for most, if not all, business processes, including project management, recruitment, sales, operations, quality, and regulatory affairs, to mention a few. Guest Introduction: Darwin Shurig, the guest, is introduced as the founder and president of a company involved in the recruitment industry, particularly within the life sciences sector. Darwin shares his journey of starting the business, highlighting his prior experience in clinical respiratory therapy and his transition to entrepreneurship nearly nine years ago. Business Challenges and Insights: Darwin discusses the challenges he faced as a newcomer to the business and recruitment industries. He emphasizes the importance of resilience, learning from failures, and the critical role of understanding market needs and analytics to sustain a business in a competitive environment. Recruitment Philosophy and Strategies: Throughout the interview, Darwin explains his approach to recruitment, focusing on the importance of specialization, understanding client needs, and delivering value without having to return fees. He stresses a high client acceptance rate and successful placement track record as indicators of his company's effectiveness. Industry Perspective and Future Outlook: Closing the conversation, Darwin reflects on the broader industry trends, including the impact of technology like AI on recruitment and other business processes. He is optimistic about the potential of new technologies to enhance business efficiency and expresses curiosity about future developments in life sciences and AI.

In this episode of Life Science Success, host Don Davis has a conversation with Dr. Mohit Jain, a physician scientist with extensive experience in physiology, biomedicine, and mass spectrometry. Dr. Jain shares his unique journey from clinical training to leading breakthroughs in mass spectrometry and computational biology. He discusses the inception of Sapient Bio, a company that leverages mass spectrometry to unlock new horizons in drug discovery and patient diagnosis by analyzing thousands of molecules in the human body. They explore the future of medicine, emphasizing personalized therapy and the potential to diagnose diseases like diabetes and Alzheimer's years in advance. Dr. Jain also sheds light on the challenges and opportunities in biotech, the impact of computational biology, and the pivotal role of Sapient Bio in pioneering the field of drug discovery. The conversation concludes with Dr. Jain's reflections on leadership, inspiration, concerns, and what excites him about his work, offering deep insights into the promising future of life sciences. Key Highlights: 01:23 Introducing Dr. Mohit Jain: A Multifaceted Scientist 02:04 The Journey to Sapient Bio: Unraveling Dr. Jain's Career Path 03:39 The Evolution of Mass Spectrometry and Its Impact on Health 06:45 Sapient Bio: Democratizing Access to Advanced Technologies 13:33 Challenges and Opportunities in Leading a Biotech Company 16:54 The Future of Drug Discovery and Personalized Medicine 23:47 Sapient Bio's Differentiation and Future Prospects 29:24 Leadership Insights and Personal Reflections from Dr. Jain

Jennifer Hawks Bland is a distinguished leader in the life sciences sector, serving as the Chief Executive Officer of NewYorkBIO, an organization at the forefront of advancing New York's life sciences ecosystem. With a rich background spanning legal practice, government affairs, and executive leadership in companies like Merck and GlaxoSmithKline, she brings a wealth of experience and insight to her role in fostering innovation and growth within the industry. Jennifer Hawks Bland, CEO of New York Bio, discussed her unique path into life sciences, transitioning from a legal background where she initially engaged with the pharmaceutical industry through mass tort defense litigation, to advocacy and lobbying roles, eventually leading her to her current position. She detailed the mission and operations of New York Bio, highlighting its role in advancing New York’s life sciences ecosystem by collaborating with early-stage companies, academic medical centers, and leveraging the state’s rich resources in life sciences for regional and statewide economic development. Hawks Bland emphasized the importance of storytelling in advocacy, drawing on her legal and lobbying background to influence policy and support the life sciences industry, both at the state and federal levels, and how this skill has been crucial in her roles leading up to and including her leadership at New York Bio. The conversation also covered the challenges and opportunities facing the life sciences sector, particularly in New York, from fostering startup growth to navigating policy and funding landscapes. She stressed the significance of collaboration across various stakeholders, including government, academia, and the private sector, to drive innovation and support the ecosystem. Hawks Bland shared her excitement for the future of life sciences, reflecting on the potential for breakthroughs in health and medicine, and the critical role of advocacy and strategic partnerships in overcoming challenges and capitalizing on opportunities within the industry.

In this episode of Life Science Success, we're thrilled to welcome Britney Winterberger, the Senior Director of North America Project Management and Clinical Operations at Tigermed. Britney brings a wealth of experience in clinical trials across various therapeutic areas and a deep personal commitment to advancing patient treatments, particularly in the fight against cancer. Britney Winterberger is the Senior Director of North America Project Management and Clinical Operations at Tigermed, with a rich career history in life sciences, inspired by a personal loss to leukemia. She initially aspired to be a pediatric oncologist but shifted towards clinical research to contribute to cancer treatment advancements. Winterberger, who was born and raised in Cincinnati, Ohio, has a Marquette University undergraduate degree in biological sciences as well as study abroad experiences. She is also a family person, emphasizing the importance of travel, outdoor activities, and being sports enthusiasts with her husband and two children. Her journey into the field of life sciences was somewhat unintentional, transitioning from a goal in pediatric oncology to clinical research due to the emotional challenges of the former. She transitioned because of a special opportunity through a family connection, which led her to a career in clinical research organizations (CROs). Throughout her career, pivotal moments included receiving a 'B' on a performance review, which was a significant learning experience for her, highlighting the importance of adaptability, innovation, and the need to work in a more agile and innovative environment. Joining Tigermed represented a culminating point where she found a space to innovate and drive meaningful change in the clinical research landscape. Winterberger discusses the evolution of clinical trials, emphasizing the shift towards patient-centric approaches, the integration of digital health technologies, and the push for decentralized clinical trials to improve patient access and compliance. She also highlights Tigermed's role in advancing clinical research through innovative trial designs and efficient patient recruitment strategies, underlining her commitment to making a difference in cancer treatment and patient care.

In this episode of Life Science Success my guest is Dr Dr. Rahul Kakkar we will dive into the life and innovations of his tremendous career. From founding groundbreaking biotech companies to his vital role at Tome Biosciences and balancing life as a practicing physician, Rahul's journey is nothing short of inspirational. Discover the cutting-edge of genomic medicine and get a peek into the mind of a true life sciences pioneer. Dr. Rahul Kakkar's Journey: Dr. Kakkar, CEO of Tome Biosciences and a distinguished biotech executive and physician scientist, shares his journey from training in the Harvard Hospital System to his disillusionment with academia's limitations on drug development. This frustration led him towards a career in biotech, underscored by his entrepreneurial spirit and the significant influence of mentors who supported him at pivotal moments. Entrepreneurial Shift and Tome Biosciences: His experiences, particularly at AstraZeneca, highlighted the challenges of navigating entrenched corporate cultures, sparking his entrepreneurial journey. This journey includes the founding of Corvidia Therapeutics and ultimately leading to his current role at Tome Biosciences, where he emphasizes a flat, open company culture focused on innovative drug development. Balancing Medicine and Leadership: Kakkar balances his roles as a physician and a biotech leader, finding real-world clinical experiences vital for grounding his work in biotech. He maintains an active part in patient care, which he finds complements his leadership in biotech, keeping his work relevant and impactful. Advancements in Biotech and Tome's Focus: Kakkar discusses the evolution of biotechnology, from monoclonal antibodies and nucleotide-based therapeutics to the future of DNA editing. At Tome Biosciences, the focus is on programmable genomic integration, aiming to create differentiated, impactful drugs. This approach underscores the importance of technology in developing meaningful new therapies. Leadership Philosophy and Inspiration: Sharing insights on leadership, Dr. Kakkar emphasizes the importance of resilience, adaptability, and making the best of situations. He finds inspiration in the human spirit's perseverance, whether in family, healthcare, or scientific discovery, driving him to overcome challenges in healthcare and biotech innovation.

This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences. Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal. Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies. ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector. Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework. Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.

This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome. On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them. Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients. Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications. One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs. Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine. His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.

In the interview, Don Davis PhD, MBA talks to Toban Zolman about his company, Kivo. Zolman takes us through his impressive journey of over 20 years in life sciences and the transformation he has witnessed in the industry. He further details the services of Kivo, stating that the company helps businesses involved in life sciences, specifically those developing clinical trials for pharmaceutical, medical device, and biotech companies, to streamline and optimize their processes. He specifically speaks about the significant shift in the industry from large pharmaceutical companies running drug trials to now being dominated by smaller companies without a product in the market yet. Regarding emerging trends, Zolman anticipates artificial intelligence will have a transformational impact on the industry. He also highlights the importance of knowing when to say "no" and making definitive decisions based on customer's needs, aligning company focus to customer growth, and maintaining transparency in their operations. 5 Key Points: Toban Zolman is the CEO of Kivo, with over 20 years of leadership experience in developing, deploying, and validating computerized systems for clinical trials. Zolman's career began in the early 2000s at an electronic submission company, pioneering the transition from paper to electronic submissions for pharmaceutical companies globally, impacting 47 out of the top 50 Pharma companies in 16 countries. At Kivo, Zolman leverages his extensive background to innovate in life sciences by integrating technology and regulatory best practices to support emerging companies in developing and marketing new drugs efficiently. Kivo stands out in the life sciences space by blending deep clinical and regulatory experience with enterprise SaaS expertise, offering a unique approach to accelerating drug development and approval processes. Zolman emphasizes the importance of adaptability, saying no to maintain focus, and the potential transformative impact of AI on drug development, viewing it as both an intimidating and exciting challenge for the future.

Revolutionizing Patient and Physician Experiences through Digital First Strategies - In this week's episode of Life Science Success, we dive into the intersection of digital innovation and healthcare commercialization with leaders from Indegene, a company revolutionizing patient and physician experiences through digital-first strategies. We'll explore the journeys of Nancy Phelan, a biopharma commercial strategy expert; Jeff Rothstein, a marketing visionary who has significantly expanded Indegene's brand and capabilities; and Kevin Patterson, a strategic thinker in medical solutions, as they share insights on driving healthcare forward in today's complex landscape. Key Takeaways: Interdisciplinary Innovation: The convergence of diverse backgrounds and expertise is driving innovation in healthcare, emphasizing the importance of storytelling and engagement in healthcare marketing. Digital Transformation: The shift towards digital and data-driven strategies is revolutionizing patient and physician experiences, making healthcare more personalized and accessible. AI's Growing Influence: Artificial intelligence is poised to transform healthcare delivery and treatment, with current applications representing just the tip of the iceberg. Navigating Market Access Challenges: Successfully bringing new treatments to market requires overcoming regulatory and accessibility hurdles, highlighting the need for strategic market access planning. Optimism for the Future: Despite challenges, there's a strong sense of optimism about the future of healthcare, driven by technological advancements and a commitment to improving patient care.

This week on Life Science Success, we're excited to welcome Donald Zinn, a seasoned professional with nearly three decades of experience in the biotech, pharmaceutical, and medical device industries. Beyond his executive roles, Don contributes to the National Institutes of Health (NIH) as a Commercialization Grant Reviewer and has played a pivotal role at Crossject, leading their needle-free auto-injector platform to global success since the onset of COVID. Donald Zinn's Background and Experience: Donald Zinn, the Vice President of US Business at Crossject, has nearly 30 years of experience in the life sciences industry. He started his career with an undergraduate degree from UMBC and went on to innovate in the field by inventing dry process microarray during his time at the Uniform Services University. His journey included roles such as lab manager at Georgetown University's HIV Center, and leadership positions in companies focused on oncology, infectious diseases, and more. Crossject's Needle-Free Auto Injector: Zinn is part of the Crossject team, working on a needle-free auto injector, which he finds to be an exciting and innovative technology. This device is designed to deliver medications quickly and without the need for needles, addressing needle phobia and improving patient compliance. Demonstration of the Injector's Ease of Use: During the podcast, a demonstration was discussed showing how the injector works, including its ability to administer medication through clothing. This feature is particularly advantageous in emergency situations where speed and ease of use are critical. Focus on Partnerships and Market Expansion: Zinn emphasizes the importance of finding the right partners worldwide to distribute Crossject's needle-free injector. The company aims to select partners based on their expertise and market presence to ensure the technology is accessible to a broad audience. Future Prospects and Industry Impact: The conversation highlighted the potential of Crossject's technology to revolutionize drug delivery, especially for emergency medications like epinephrine. The ease of use, coupled with the effectiveness of the needle-free injector, presents a significant advancement in patient care and medication administration.

In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services. Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD. Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies. Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups. Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward. Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.

In this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur. Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years. Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine. His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine. Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes. He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.

Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc. Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval. Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval. His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves. O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute. He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry. O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.

In this episode of Life Science Success, my guest is Matt Hill, Ph.D. Matt is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area committed to revolutionizing synthetic biology workflows with innovative DNA writing technology. Background and Experience: Matt Hill has a Ph.D. in genetics from Stanford University and was initially attracted to the Bay Area for its vibrant startup ecosystem. After completing his Ph.D., he joined Nera, a leading molecular diagnostics company, where he contributed to product development and new capabilities, particularly in massively multiplex PCR technology. Journey to Founding Elegen: Hill's experience at Nera, especially in DNA synthesis and production challenges, led him to identify DNA production as a critical bottleneck in life sciences. His interest in solving complex problems and connecting technology areas motivated him to found Elegen to address these challenges in DNA synthesis and production. Elegen's Impact and Infinia DNA: Elegen's product, Infinia DNA, aims to streamline workflows in life sciences, providing researchers with faster, more accurate DNA synthesis. This technology impacts various fields, including therapeutics and synthetic biology, by enabling quicker and more efficient product development cycles. Leadership and Vision: As a leader, Hill emphasizes inspiration, encouragement, and problem-solving. He discusses the importance of Elegen's technology in advancing fields like personalized therapeutics and its potential in addressing major health challenges. Hill also highlights the need for more investment in foundational research and development to foster scientific progress.

In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US. The key highlights from the interview: Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject. His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment. Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue. Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively. His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging. Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes. He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event. The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.

In this episode of Life Science Success, my guest is Dr. Lishan Aklog. Dr. Aklog is the CEO of Lucid Diagnostics he also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception. Dr. Lishan Aklog's Background: Dr. Aklog, CEO of Lucid Diagnostics and executive chairman of PAVmed’s subsidiary Varys Health, was a cardiothoracic surgeon with a strong interest in technological innovation in medicine. He has an extensive background in academic cardiac surgery and was actively involved in medical device innovation. Transition to Entrepreneurship: Transitioning from a successful career in cardiac surgery, Dr. Aklog co-founded Lucid Diagnostics and PAVmed. He ventured into medical device entrepreneurship, focusing on developing and commercializing innovative technologies. He was instrumental in creating and selling medical devices, notably a device for non-surgically removing clots. Lucid Diagnostics and Focus on Cancer Detection: Under Dr. Aklog’s leadership, Lucid Diagnostics specializes in early cancer detection, particularly esophageal cancer. Dr. Aklog emphasizes the importance of pre-cancer detection and prevention, highlighting the challenges in raising awareness and adherence to screening guidelines. Challenges and Achievements: A significant challenge in Dr. Aklog's journey has been raising capital to bring innovative technologies to market. Despite these challenges, Lucid Diagnostics has made substantial progress, especially in gaining payer coverage and launching large-scale screening programs. Leadership and Vision: Dr. Aklog's leadership philosophy centers on building a culture of success, teamwork, and innovation. He stresses the importance of surrounding oneself with talented individuals and working cohesively towards a shared mission, with a particular focus on impacting patient lives through advanced medical technologies.

In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint. Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain. ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself. The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach. Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.

In this episode of Life Science Success, my guest is Tom Hartman. Tom is the President and CEO of the International Society of Pharmaceutical Engineering (ISPE), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle. In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.

In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs. Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion. Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion. Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens. Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology. Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.